Outcomes after major bleeding , including stroke or non-central nervous system embolism ( 4.7 % rivaroxaban vs. 5.4 % warfarin ; HR 0.89 ; 95 % CI 0.42-1 .88 ) and all-cause death ( 20.4 % rivaroxaban vs. 26.1 % warfarin ; HR 0.69 , 95 % CI 0.46-1 .04 ) were similar in patients treated with rivaroxaban and warfarin ( interaction P = 0.51 and 0.11 ) .